Research News and Views
LRF regularly covers lymphoma research news and publishes stories about research advances and issues in the field. Often these stories are connected to past grantees or members of an LRF researcher group such as the Scientific Advisory Board.
ASH Presentations Demonstrate Quality of Life and Risk Factors are Crucial Research Areas in Lymphoma
A subset of ASH presentations focused on the impact of non-pharmaceutical treatment issues such as patient quality of life, maintenance scans, and the presence or absence of various risk factors.
ASH Presentations on NHL Novel Therapies Highlight Expanding Options for Patients
The ASH Annual Meeting, convened in December 2014, highlighted the expanding array of novel therapy treatments showing promise for non-Hodgkin lymphoma (NHL) patients.
ASH 2014 Features Promising New Treatment Strategies for Hodgkin Lymphoma
Among the many exciting clinical trials results presented at the ASH Annual Meeting in December 2014 were three significant studies for Hodgkin Lymphoma (HL) patients.
Double hit lymphoma studies hot topic in Blood, at ASH Annual Meeting
The rare but aggressive subtype of B-cell lymphoma has been the focus of several studies this fall, in Blood and at the 2014 ASH Annual Meeting, as researchers seek to identify effective treatment options for DHL patients.
Research News and Views Home
Featured Researcher Profiles
Lymphoma Research Foundation Grantee Identifies Mechanism Behind Resistance to Ibrutinib in MCL
Selina Chen-Kiang, PhD, an LRF grantee, and her colleagues have identified both the molecular mechanism that causes some mantle cell lymphoma (MCL) patients to be resistant to ibrutinib (Imbruvica), and ways to overcome that resistance, according to their recently published study in Cancer Discovery.
LRF Grantee Identifies Genetic Marker Affecting Outcomes for DLBCL Patients
A study authored by a LRF Career Development Award winner identified a genetic marker that may indicate diffuse large B-cell lymphoma (DLBCL) patients who will not respond well to standard treatments.
Study Suggests Treating Lymphoma during Pregnancy Does Not Increase Risk to Mother or Child
Several researchers with ties to the Lymphoma Research Foundation (LRF) contributed to a recently published study examining the treatment, complications, and outcomes for women who receive a diagnosis of lymphoma during pregnancy.
Ofatumumab Shows Promise As Alternative Agent for Relapsed/Refractory B-Cell Lymphoma
A study released in the July 25 issue of Blood suggests the new drug ofatumumab may be a promising alternative to rituximab in combination therapy for B-cell lymphoma patients for whom first line therapies fail.
Breakthrough Therapy Ibrutinib Effective in CLL and MCL Lymphomas
Two studies recently published in the New England Journal of Medicine provide additional evidence that the targeted therapy ibrutinib is an effective treatement for multiple types of NHL.
Highlights from ASCO 2013
The annual meeting of the American Society of Clinical Oncology (ASCO) took place in Chicago from May 31 through June 4, 2013, and the work of several of the Lymphoma Research Foundation's (LRF) Scientific Advisory Board (SAB) members were among the studies presented.
Federal Sequester's Impact on NIH Funding Has Serious Consequences for Lymphoma Research
The NIH is being dramatically affected by the budget cuts mandated by the federal sequester. For people and organizations invested in advancing cancer research, these cuts have particularly serious consequences.
SAB Member Leads Study Identifying Master Regulator Protein in B-Cell Lymphomas
A study led by an LRF Scientific Advisory Board (SAB) member suggests a new class of drug inhibitors may affect a broader range of lymphoma patients than originally thought.
SAB Members' Trial Shows Promise In Treating B-Cell Lymphoma Patients Without Radiation
A trial conducted by researchers at the National Cancer Institute (NCI), including two members of LRF's Scientific Advisory Board, may point the way towards treating mediastinal B-cell lymphoma patients without radiation.
A conversation with Dr. Kim Robien on living with lymphoma – a guide to nutrition
Following on from the current spring edition of LRF’s Research Report which features an article from Dr. Kim Robien, PhD, RD, CSO, George Washington University, School of Public Health and Health Services, we asked Dr. Robien to share some of the most common questions that she is asked by patients on nutrition and managing a lymphoma diagnosis.
LRF grant recipient publishes promising study offering hope to patients who fail to respond to chemotherapy or who relapse
Two-time LRF Mantle Cell Lymphoma (MCL) Initiative Award recipient, Ajay Gopal, M.D., Associate Professor, Department of Medicine, Division of Oncology, at the Seattle Cancer Care Alliance, has recently published a promising study in the British Journal of Hematology, which may solve the dilemma of how to effectively treat patients when chemotherapy regimens fail to make an impact in their initial treatment or following relapse.
SAB Chair Elect, Leo I. Gordon, co-authors study developing nontoxic 'gold' treatment for B-Cell Lymphoma patients
A new study by C. Shad Thaxton, MD and Leo, I. Gordon, MD both of Northwestern University Medical Center, provides new hope for those living with B-Cell lymphoma, the most common form of lymphoma.
Reducing Treatment Toxicity - Dr. Ari Melnick, LRF Scientific Advisory Board (SAB) Member, leads study to improve patient outcomes
In a large scale study that included several institutions from the US, Spain and Canada, lead investigator and LRF SAB member, Dr. Ari Melnick of New York Presbyterian Hospital, Weill Cornell Medical Center, recently published important results in the journal Cancer Cell that have the potential to create effective targeted therapies that will reduce the toxicity of treatment for lymphoma patients.
LRF Mantle Cell Lymphoma Consortium and SAB members make important strides toward the treatment of Burkitt lymphoma
The Lymphoma Research Foundation (LRF) is pleased to announce the recent achievements of Dr. Sandeep Dave of Duke University Medical Center in Durham, North Carolina and a member of the LRF's Mantle Cell Consortium (MCLC), as well as study co-authors that include Dr. Chris Flowers and Dr. Leo Gordon, members of LRF's Scientific Advisory Board (SAB), in their work on Burkitt's lymphoma.
LRF Grantee opens the first in-human clinical trial with a new approach to immunotherapy in patients with high risk B-Cell lymphoma who have undergone ASCT
Unfortunately, conventional chemotherapy has limited potential to cure recurrent lymphomas. However, with the advent of biological therapies, such as infusing T cells, treatments can target disease employing mechanisms independent of chemotherapy and radiation. One promising approach to harnessing the tumor fighting ability of T cells is using gene therapy to express a chimeric antigen receptor (CAR), an innovative approach currently being used by LRF grantee, Dr. Laurence Cooper of MD Anderson Cancer Center.
SAB Member, Jonathan W. Friedberg's study demonstrates the importance of careful evaluation at diagnosis of FL patients for progression-free survival
Dr. Jonathan W. Friedberg, Chief, Hematology/Oncology at URMC Wilmot Cancer Center and Lymphoma Research Foundation Scientific Advisory Board member, is lead author on an exciting new study believed to be the largest investigation of early-stage follicular lymphoma (FL) in recent years.
Former LRF Fellow Receives National Institutes of Health K07 Career Development Award to Continue Research Evaluating Association between Vitamin D and Lymphoma Prognosis
The Lymphoma Research Foundation (LRF) is proud to announce that one of our former postdoctoral fellows, Jennifer Kelly, PhD, MPH, has received a K07 Career Development Award (CDA) from the National Institutes of Health (NIH).
Promising Clinical Trial Results for Personalized Cancer Vaccine
Results of a Phase II clinical trial suggest that BiovaxID vaccine following rituximab combination therapy correlates with overall survival and time-to-next treatment benefits in mantle cell lymphoma patients. BiovaxID is also expected to be the first personalized cancer vaccine for the treatment of follicular lymphoma.
LRF's Newest Grantees Summer 2012 – The Future of Lymphoma Research
The Lymphoma Research Foundation (LRF) is pleased to announce our seven new grant recipients for Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), and Follicular Lymphoma (FL) research grants. These grants are awarded to experienced researchers pursuing the development of innovative treatments.
Clinical Trial Results Find Targeted Drug Ibrutinib May Benefit Some Patients with Diffuse Large B-Cell Lymphoma
Trials were co-led by LRF Scientific Advisory Board (SAB) members Drs. Louis Staudt and Wyndham Wilson of the National Cancer Center's Center for Cancer Research.
9th Annual MCL Scientific Workshop
The Lymphoma Research Foundation hosted its 9th Annual MCL Scientific Workshop in Atlanta, GA this April with over 70 MCL researchers attending from institutions worldwide. This year's workshop included 24 presentations delivered by prestigious MCL researchers and scientists with focus primarily on pathogenesis, the state of MCL today, immunology/immunotherapies, pre-clinical and clinical approaches, pre-clinical therapies and clinical therapies, or B-cell receptor pathways.
LRF's Newest Grantees Winter 2012 – The Future of Lymphoma Research
The Lymphoma Research Foundation (LRF) is pleased to introduce our seven newest grantees. In the fall of 2011, LRF's Scientific Advisory Board (SAB) reviewed applications for two different grant programs: the Clinical Investigator Career Development Award (CDA) and the Post-Doctoral Fellowship.
Research Directions in Follicular Lymphoma
Ten distinguished follicular lymphoma (FL) experts and six Lymphoma Research Foundation (LRF) board members gathered in Houston, TX on October 27, 2011 to develop priorities for the LRF's FL Research Program
Make a Difference for Burkitt Lymphoma – Join the BL Genome Sequencing Project (BLGSP)
Burkitt Lymphoma (BL) is an aggressive (fast growing) form of B-cell non-Hodgkin lymphoma that occurs most frequently in children and young adults.
LRF's Newest Grantees Fall 2011 – The Future of Lymphoma Research
The Lymphoma Research Foundation (LRF) is pleased to introduce our seven newest grantees! In the summer of 2011, LRF's Scientific Advisory Board reviewed applications for two different programs: Mantle Cell Lymphoma (MCL) Exploratory/Developmental Grants and Follicular Lymphoma (FL) Clinical Studies Awards.
LRF Career Development Award Recipient Lauded for Successful Mantle Cell Clinical Trial
Joshua Brody, MD (Instructor, Division of Oncology, Department of Medicine, Stanford University School of Medicine) has found much success since his clinical trial studying the efficacy of immunotherapy in mantle cell lymphoma (MCL) commenced two years ago. After being awarded with the Lymphoma Research Foundation Clinical Investigator Career Development Award in 2007, Dr. Brody was able to apply his pre-clinical research in cancer vaccines to his current trial. The study protocol has shown significant positive effects on treatment of the disease and Dr. Brody and his team have been lauded by both the American Society of Clinical Oncology (ASCO) and the Swiss Cancer League.
Lymphoma Research Foundation Hosts Groundbreaking Workshop on CLL Treatment
The Lymphoma Research Foundation brought together leading experts and industry insiders in the field of chronic lymphocytic leukemia (CLL) last month for a discussion forum on disease treatment. The meeting, held outside of Washington DC, was the first of its kind hosted by LRF and was chaired by LRF Scientific Advisory Board Chair Bruce D. Cheson, MD, FACP, FAAAS (Georgetown University Hospital).
Former LRF SAB Chair Edits, LRF Grantees Contribute to Special Publication on Lymphoma Research
The Journal of Clinical Oncology, a publication of the American Society of Clinical Oncology, recently published a special edition by former Lymphoma Research Foundation (LRF) Scientific Advisory Board (SAB) Chair Richard I. Fisher, MD. Highlighting the latest discoveries and opportunities in lymphoma research, the online publication includes contributions from several LRF SAB members and grantees.
LRF's Newest Grantees Spring 2011 – The Future of Lymphoma Research
The Lymphoma Research Foundation (LRF) is pleased to introduce our six newest grantees! In the Fall of 2010, LRF's Scientific Advisory Board reviewed applications for three different programs: Post-Doctoral Fellowships, Career Development Awards (CDA) and Mantle Cell Lymphoma (MCL) Correlative Grants.
Report from 2010 MCLC Scientific Workshop Published in Leukemia & Lymphoma
The public has a unique opportunity to access detailed summaries of the presentations given at the March 2010 meeting of the Mantle Cell Lymphoma Consortium now published in the January issue of the scientific journal and available online for one month.
2010 Lymphoma Research Findings Presented at the ASH Annual Meeting
The 52nd Annual Meeting of the American Society of Hematology (ASH) was held December 4-7, 2010 at the Orange County Convention Center in Orlando, Florida. The conference was the venue for the presentation of much of the year's breakthrough research on lymphoma and other blood-related disorders. The lymphoma community anxiously awaits the discoveries announced at ASH each year and the Lymphoma Research Foundation (LRF) has compiled summaries of the most important findings to provide a general understanding of the biggest advances in lymphoma research in 2010.
SAB Members Receive Federal Funding
Two members of LRF's Scientific Advisory Board (SAB) become principal investigators in an $11.5 million lymphoma SPORE grant.
Research Report Newsletter
LRF regularly reports on the latest lymphoma research news from our Fellows and grant recipients as well as the latest findings presented at major conferences such as ASH and ASCO. See archived Research Reports
Featured LRF Researchers
Every month, the Lymphoma Research Foundation will spotlight a successfull grantee, groundbreaking researcher or active Scientific Advisory Board (SAB) or Mantle Cell Lymphoma Consortium (MCLC) member. Please enjoy reading about their accomplishments.
The LRF's Mantle Cell Lymphoma Research Initiative has made great strides since an anonymous donor jump started the program in 2003. Now an anonymous donor has pledged $500,000 to stimulate donations to continue the effort. With this new pledge of $500,000, we have the opportunity to increase funding for mantle cell research by $1 million. To donate to the Mantle Cell Lymphoma Research Grant, call Diane Blum or Evelyn Lipori at (800) 235-6848 or donate online at www.lymphoma.org/MCLresearch.
LRF Board Members Michael Werner and Tom Condon, along with their families, have committed a total of $200,000 in the form of a challenge grant to encourage other donors to make an investment in follicular lymphoma (FL) research. The goal of the Werner/Condon Challenge is to raise $1 million by December 31, 2011, thus enabling LRF to fund two additional FL-specific grants in 2011! If you are interested in donating to the Werner/Condon Follicular Lymphoma Research Challenge, click here.